Xyloketal B Attenuates Fatty Acid-Induced Lipid Accumulation via the SREBP-1c Pathway in NAFLD Models
The goal of this study was to examine the effects of xyloketal B on nonalcoholic fatty liver disease (NAFLD) and to explore the molecular mechanisms underlying its effects in both in vivo and in vitro models. We discovered an association between xyloketal B and the sterol regulatory element-binding...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2017-06-01
|
| Series: | Marine Drugs |
| Subjects: | |
| Online Access: | http://www.mdpi.com/1660-3397/15/6/163 |
| _version_ | 1798006282337124352 |
|---|---|
| author | Youying Zhang Tian Meng Ling Zuo Yu Bei Qihao Zhang Zhijian Su Yadong Huang Jiyan Pang Qi Xiang Hongtu Yang |
| author_facet | Youying Zhang Tian Meng Ling Zuo Yu Bei Qihao Zhang Zhijian Su Yadong Huang Jiyan Pang Qi Xiang Hongtu Yang |
| author_sort | Youying Zhang |
| collection | DOAJ |
| description | The goal of this study was to examine the effects of xyloketal B on nonalcoholic fatty liver disease (NAFLD) and to explore the molecular mechanisms underlying its effects in both in vivo and in vitro models. We discovered an association between xyloketal B and the sterol regulatory element-binding protein-1c (SREBP-1c) signaling pathway, which is related to lipid metabolism. Mice were dosed with xyloketal B (5, 10 and 20 mg/kg/d) and atorvastatin (15 mg/kg/d) via intraperitoneal injection once daily for 40 days after being fed a high fat diet plus 10% high fructose liquid (HFD+HFL) for 8 weeks. Xyloketal B significantly improved HFD+HFL-induced hepatic histological lesions and attenuated lipid and glucose accumulation in the blood as well as lipid accumulation in the liver. Xyloketal B increased the expression of CPT1A, and decreased the expression of SREBP-1c and its downstream targeting enzymes such as ACC1, ACL, and FAS. Xyloketal B also significantly reduced lipid accumulation in HepG2 cells treated with free fatty acids (FFAs). These data suggested that xyloketal B has lipid-lowering effects via the SREBP-1c pathway that regulate lipid metabolism. Thus, targeting SREBP-1c activation with xyloketal B may be a promising novel approach for NAFLD treatment. |
| first_indexed | 2024-04-11T12:52:21Z |
| format | Article |
| id | doaj.art-e6351a2f24fd4878ba974a65d82e428e |
| institution | Directory Open Access Journal |
| issn | 1660-3397 |
| language | English |
| last_indexed | 2024-04-11T12:52:21Z |
| publishDate | 2017-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Marine Drugs |
| spelling | doaj.art-e6351a2f24fd4878ba974a65d82e428e2022-12-22T04:23:10ZengMDPI AGMarine Drugs1660-33972017-06-0115616310.3390/md15060163md15060163Xyloketal B Attenuates Fatty Acid-Induced Lipid Accumulation via the SREBP-1c Pathway in NAFLD ModelsYouying Zhang0Tian Meng1Ling Zuo2Yu Bei3Qihao Zhang4Zhijian Su5Yadong Huang6Jiyan Pang7Qi Xiang8Hongtu Yang9Institute of Biomedicine & Guangdong Provincial Key Laboratory of Bioengineering Medicine, Jinan University, Guangzhou 510632, ChinaInstitute of Biomedicine & Guangdong Provincial Key Laboratory of Bioengineering Medicine, Jinan University, Guangzhou 510632, ChinaInstitute of Biomedicine & Guangdong Provincial Key Laboratory of Bioengineering Medicine, Jinan University, Guangzhou 510632, ChinaInstitute of Biomedicine & Guangdong Provincial Key Laboratory of Bioengineering Medicine, Jinan University, Guangzhou 510632, ChinaInstitute of Biomedicine & Guangdong Provincial Key Laboratory of Bioengineering Medicine, Jinan University, Guangzhou 510632, ChinaInstitute of Biomedicine & Guangdong Provincial Key Laboratory of Bioengineering Medicine, Jinan University, Guangzhou 510632, ChinaInstitute of Biomedicine & Guangdong Provincial Key Laboratory of Bioengineering Medicine, Jinan University, Guangzhou 510632, ChinaSchool of Chemistry and Chemical Engineering, Sun Yat-Sen University, Guangzhou 510275, ChinaInstitute of Biomedicine & Guangdong Provincial Key Laboratory of Bioengineering Medicine, Jinan University, Guangzhou 510632, ChinaDepartment of Pharmacy, Jinan University, Guangzhou 510632, ChinaThe goal of this study was to examine the effects of xyloketal B on nonalcoholic fatty liver disease (NAFLD) and to explore the molecular mechanisms underlying its effects in both in vivo and in vitro models. We discovered an association between xyloketal B and the sterol regulatory element-binding protein-1c (SREBP-1c) signaling pathway, which is related to lipid metabolism. Mice were dosed with xyloketal B (5, 10 and 20 mg/kg/d) and atorvastatin (15 mg/kg/d) via intraperitoneal injection once daily for 40 days after being fed a high fat diet plus 10% high fructose liquid (HFD+HFL) for 8 weeks. Xyloketal B significantly improved HFD+HFL-induced hepatic histological lesions and attenuated lipid and glucose accumulation in the blood as well as lipid accumulation in the liver. Xyloketal B increased the expression of CPT1A, and decreased the expression of SREBP-1c and its downstream targeting enzymes such as ACC1, ACL, and FAS. Xyloketal B also significantly reduced lipid accumulation in HepG2 cells treated with free fatty acids (FFAs). These data suggested that xyloketal B has lipid-lowering effects via the SREBP-1c pathway that regulate lipid metabolism. Thus, targeting SREBP-1c activation with xyloketal B may be a promising novel approach for NAFLD treatment.http://www.mdpi.com/1660-3397/15/6/163Xyloketal BNAFLDSREBP-1c pathway |
| spellingShingle | Youying Zhang Tian Meng Ling Zuo Yu Bei Qihao Zhang Zhijian Su Yadong Huang Jiyan Pang Qi Xiang Hongtu Yang Xyloketal B Attenuates Fatty Acid-Induced Lipid Accumulation via the SREBP-1c Pathway in NAFLD Models Marine Drugs Xyloketal B NAFLD SREBP-1c pathway |
| title | Xyloketal B Attenuates Fatty Acid-Induced Lipid Accumulation via the SREBP-1c Pathway in NAFLD Models |
| title_full | Xyloketal B Attenuates Fatty Acid-Induced Lipid Accumulation via the SREBP-1c Pathway in NAFLD Models |
| title_fullStr | Xyloketal B Attenuates Fatty Acid-Induced Lipid Accumulation via the SREBP-1c Pathway in NAFLD Models |
| title_full_unstemmed | Xyloketal B Attenuates Fatty Acid-Induced Lipid Accumulation via the SREBP-1c Pathway in NAFLD Models |
| title_short | Xyloketal B Attenuates Fatty Acid-Induced Lipid Accumulation via the SREBP-1c Pathway in NAFLD Models |
| title_sort | xyloketal b attenuates fatty acid induced lipid accumulation via the srebp 1c pathway in nafld models |
| topic | Xyloketal B NAFLD SREBP-1c pathway |
| url | http://www.mdpi.com/1660-3397/15/6/163 |
| work_keys_str_mv | AT youyingzhang xyloketalbattenuatesfattyacidinducedlipidaccumulationviathesrebp1cpathwayinnafldmodels AT tianmeng xyloketalbattenuatesfattyacidinducedlipidaccumulationviathesrebp1cpathwayinnafldmodels AT lingzuo xyloketalbattenuatesfattyacidinducedlipidaccumulationviathesrebp1cpathwayinnafldmodels AT yubei xyloketalbattenuatesfattyacidinducedlipidaccumulationviathesrebp1cpathwayinnafldmodels AT qihaozhang xyloketalbattenuatesfattyacidinducedlipidaccumulationviathesrebp1cpathwayinnafldmodels AT zhijiansu xyloketalbattenuatesfattyacidinducedlipidaccumulationviathesrebp1cpathwayinnafldmodels AT yadonghuang xyloketalbattenuatesfattyacidinducedlipidaccumulationviathesrebp1cpathwayinnafldmodels AT jiyanpang xyloketalbattenuatesfattyacidinducedlipidaccumulationviathesrebp1cpathwayinnafldmodels AT qixiang xyloketalbattenuatesfattyacidinducedlipidaccumulationviathesrebp1cpathwayinnafldmodels AT hongtuyang xyloketalbattenuatesfattyacidinducedlipidaccumulationviathesrebp1cpathwayinnafldmodels |